Clinical trials: Lung Cancer, Small Cell
- Condition Lung Cancer, Small Cell
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Anaplastic Lymphoma Kinase (ALK)- Positive Tumors, Non-small Cell Lung Cancer (NSCLC)
Managed Access Programs for LDK378, Ceritinib
The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.
- Trial name
- NCT05100134
- Testing
- ceritinib
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer, Non-Small Cell Lung Cancer
A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES)
This is an observational study designed to follow patients with metastatic or locally advanced and unresectable CRC or locally advanced or metastatic NSCLC (excluding predominant squamous histology) who are receiving Avastin in…
- Trial name
- ARIES (NCT00388206)
- Volunteers
- 3,998 people
- Sponsor
- Genentech, Inc.
Non-Small Cell Lung Cancer
Clinical Evaluation of Genetron Lung Cancer Panel in Non-small Cell Lung Cancer Patients
The purpose of this trail is to evaluate the performance of Genetron lung cancer panel in non-small cell lung cancer patients using semiconductor sequencing method.
- Trial name
- NCT05023746
- Testing
- Genetron lung cancer panel
- Where
- 4 sites in China
- Volunteers
- 1,052 people
- Sponsor
- Genetron Health
Lung Cancer, Small Cell
Regulatory Hycamtin(Oral) PMS
Non-interventional, open-label, single group, multicentric post-marketing surveillance to monitor the safety and effectiveness of Topotecan administered in Korean patients according to the prescribing information
- Trial name
- Hycamtin PMS (NCT01037023)
- Testing
- Topotecan
- Where
- 2 sites in South Korea
- Volunteers
- 92 people
- Sponsor
- GlaxoSmithKline
Non-small Cell Lung Cancer
Understanding Non-small Cell Lung Cancer Patient Characteristics, Treatment Patterns and Outcomes
This is a retrospective, cross-sectional, non-interventional, multi-country survey-based chart audit study to evaluate real-world treatment patterns, patient clinical profiles, and clinical outcomes among a NSCLC patients…
- Trial name
- UNCOVER (NCT07215026)
- Where
- India
- Volunteers
- 833 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS
This is a local, prospective, non-interventional, regulatory postmarketing surveillance study. The objectives of this study are to assess the safety and efficacy of single agent Tagrisso (Osimertinib, hereinafter "the study…
- Trial name
- KOREA-PLUS (NCT03918304)
- Where
- 10 sites in South Korea
- Volunteers
- 923 people
- Sponsor
- AstraZeneca
Carcinoma, Midline
A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers
This study is divided into two parts; Part 1 of the study is a dose escalation phase to select the recommended dose for Part 2 based on the safety, pharmacokinetic, and pharmacodynamic profiles observed after oral administration…
- Trial name
- NCT01587703
- Testing
- GSK525762
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 196 people
- Sponsor
- GlaxoSmithKline
Lung Neoplasms
DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records.
- Trial name
- DeniLA (NCT07109154)
- Where
- 7 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Non Small Cell Lung Cancer
FHND9041 Versus Afatinib for Non-small Cell Lung Cancer
The goal of this clinical trial is to evaluate the effectiveness and safety of FHND9041 compared to afatinib as first-line treatments for epidermal growth factor receptor mutation-positive (EGFRm+) locally advanced or metastatic…
- Trial name
- FHND9041 (NCT06759857)
- Testing
- FHND9041, Afatinib
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
Lung Cancer
Reveal the Patterns of Presentation, Management and Outcome of Patients With SCLC and Stage III NSCLC in Saudi Arabia:
A retrospective, multi-centre, observational study to describe the treatment patterns, the demographic, clinical outcomes, treatment effectiveness, and healthcare resource utilization (HCRU) for patients diagnosed with primary…
- Trial name
- REVEAL (NCT04836975)
- Where
- Saudi Arabia
- Volunteers
- 45 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Observations From Long Term Responders in the Gefitinib (Iressa) Expanded Access Program (EAP)
The purpose of the study is to determine patient characteristics from patients that have used Iressa for a period of minimal 3 years.
- Trial name
- NCT01103089
- Where
- 11 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
This is an Expanded Access Program (EAP) that will give the participants access to the drug SL-28 before it is approved by the FDA.
- Conditions
- Neuroblastoma in Children, Neuroblastoma, Recurrent, Refractory, Advanced Cancer, Advanced Malignant Neoplasm
- Trial name
- NCT06872489
- Testing
- SL-28.
- Sponsor
- Second Life Therapeutics
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Colorectal Cancer, Locally Advanced
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain.
- Conditions
- Colorectal Cancer, Locally Advanced, Metastatic Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT00819169
- Testing
- AMG 479, AMG 655
- Volunteers
- 89 people
- Sponsor
- NantCell, Inc.
NSCLC, Non Small Cell Lung Cancer
A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer
For patients diagnosed with early (Stage I) non-small cell lung cancer, a lobe of lung is usually removed at surgery to treat the cancer.
- Trial name
- NCT01237171
- Testing
- Cesium-131 Brachytherapy Seed
- Where
- United States
- Sponsor
- IsoRay Medical, Inc.
Carcinoma, Small Cell
IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer
To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch
- Trial name
- NCT04854590
- Where
- 18 sites in Japan
- Volunteers
- 248 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa
The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.
- Trial name
- NCT01000740
- Testing
- EGFR Mutation Test, Ki-67 protein expression
- Where
- 9 sites in China
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Non Small Cell Lung Cancer
Testing of DNA Extracted From Tumor Tissue Biopsy Samples Using Therascreen KRAS RGQ PCR Kit
A Non-interventional Biomarker Study for the testing of DNA extracted from tumour tissue biopsy samples, using the therascreen® KRAS RGQ PCR Kit, from patients with Non-Small Cell Lung Cancer, screened in Clinical Study (Protocol…
- Trial name
- NCT05360225
- Testing
- therascreen® KRAS RGQ PCR Kit
- Where
- United Kingdom
- Volunteers
- 5,000 people
- Sponsor
- QIAGEN Gaithersburg, Inc
Advanced Endstage Solid Carcinomas in Adults
CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors
To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and rate of disease stabilization, as defined by the below primary and secondary endpoints, in patients with Non-Small Cell Lung Carcinoma…
- Trial name
- CAP7-1 (NCT02094560)
- Testing
- CAP7.1
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- CellAct Pharma GmbH